MK-677, also known as Ibutamoren, is a compound that acts as a potent, orally active, non-peptidic agonist of the ghrelin receptor and a growth hormone secretagogue. This means it stimulates the body's natural production and release of growth hormone (GH) and insulin-like growth factor 1 (IGF-1) without directly introducing exogenous growth hormone. Unlike many other compounds that influence growth hormone, MK-677 does not typically suppress the body's own GH production in the long term; instead, it works by mimicking the action of ghrelin, a natural hormone that plays a key role in regulating appetite and GH release. The compound is being investigated for its potential in various clinical applications, including treating growth hormone deficiency, muscle wasting, and osteoporosis. However, it is not approved by regulatory bodies like the FDA for these uses, and it is primarily found in research chemical contexts or as a dietary supplement ingredient in some regions. Its use in humans is largely based on preclinical studies and limited clinical trials, as well as anecdotal reporting from individuals who use it for performance and health-related goals.
MK-677 has a relatively long half-life of approximately 24 hours, which allows for once-daily dosing. It does not possess anabolic androgenic properties. Its mechanism of action, by stimulating the release of endogenous growth hormone and IGF-1, makes it a compound of interest for individuals seeking to enhance muscle mass, improve recovery from exercise, and potentially support aspects of longevity. However, it is crucial to recognize that the long-term safety and efficacy of MK-677 in healthy individuals for these purposes are still under investigation, and much of the available information comes from pre-clinical research or non-human studies. The journey from research chemical to approved therapeutic agent involves rigorous testing and regulatory oversight, which MK-677 has not yet completed for widespread clinical use. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Deep dive
Tap a section to expand.
Known interactions
Category rule: glp1 × supplement
Note
GLP-1 medications slow stomach emptying, changing how/when oral supplements absorb; rapid weight loss raises the importance of protein and micronutrients.
Time oral supplements when nausea is lowest; prioritize protein and micronutrients; discuss with your provider.
Category rule: supplement × medication
Note
Some supplements change how the body processes medications (absorption, liver enzymes, or additive effects).
Specific pairs are checked against a licensed drug database and shown with their own severity. Always confirm with your provider or pharmacist.
Compound-pair rule
Note
MK-677 can transiently increase fasting glucose; metformin may offset but monitor.
Monitor fasting glucose and HbA1c when combining.
Compound-pair rule
Note
MK-677 raises IGF-1 and can transiently raise glucose; GLP-1 helps.
Monitor glucose; combine only with clinician oversight.
Frequently asked
Sources referenced
* NIH Office of Dietary Supplements
* MedlinePlus
* PubChem
* Mayo Clinic
* Cochrane Database of Systematic Reviews
* DrugBank
Stackwise compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician.
Related compounds
Others in the supplement category or studied for the same goals.
